share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4：持股變動聲明-高管 Bruno Julianne
美股sec公告 ·  05/25 04:20
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG's Chief Operating Officer, Julianne Bruno, has been involved in a transaction with the company's stock on May 23, 2024. However, the details regarding the type of action, status, number of shares involved, nature of shares, transaction price, and the total value of shares after the transaction have not been disclosed. This information is crucial for investors to understand the implications of the insider's actions on their investment decisions.
CRISPR Therapeutics AG的首席運營官朱麗安·布魯諾於2024年5月23日參與了與該公司股票的交易。但是，有關行動類型、地位、所涉股票數量、股票性質、交易價格和交易後股票總價值的詳細信息尚未披露。這些信息對於投資者了解內部人士的行爲對其投資決策的影響至關重要。
CRISPR Therapeutics AG的首席運營官朱麗安·布魯諾於2024年5月23日參與了與該公司股票的交易。但是，有關行動類型、地位、所涉股票數量、股票性質、交易價格和交易後股票總價值的詳細信息尚未披露。這些信息對於投資者了解內部人士的行爲對其投資決策的影響至關重要。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。